Literature DB >> 33262570

Clinical Dry Eye and Meibomian Gland Features Among Dry Eye Patients in Rural and Urban Ghana.

Eugene Appenteng Osae1,2, Reynolds Kwame Ablordeppey1, Jens Horstmann2, David Ben Kumah1, Philipp Steven2,3.   

Abstract

AIM: To compare differences in clinical dry eye features and meibomian gland health status between dry eye patients from rural and urban populations in Ghana.
METHODS: We examined 211 (rural=109, urban=102) participants with subjective dry eye symptoms. Tear film break -up time (TBUT), Schirmer's test and ocular surface staining (OSS) were assessed. Symptoms were evaluated using the SPEED II questionnaire. Meibomian glands (MG) in the right eye upper (UL) and lower lids (LL) were imaged using a custom meibographer. MG area was determined by intensity threshold segmentation using Image J software. MG loss (MGL) was also graded based on Pult's grading scheme. Mann-Whitney, Spearman correlation, chi-square and odds analyses were performed; p<0.05 was considered significant.
RESULTS: Rural participants showed greater SPEED scores, reduced TBUT, and lower Schirmer scores, p <0.05. The proportion of rural participants with MGL were significantly more (82.3%) than urban participants (63.3%), p <0.05. They also showed greater MGL than urban participants, p <0.05. Chi-square test revealed significantly different meiboscale distributions (UL: χ2 =13.58, LL: χ2 =15.29) between the groups, p <0.05. Overall significant relationships were observed between MGL and age [rs= 0.61], OSS [rs= 0.35], TBUT [rs= -0.52], and Schirmer scores [rs= -0.40], p <0.05.
CONCLUSION: The data suggest that the participants from the rural population have worse dry eye and meibomian gland health status than those from the urban population. The significant relationships between the various clinical variables suggest important links between MGD and DED. Subtle differences in the everyday working and living environment could likely account for the differences in the severity of DED and MGD between the two groups. And considering the increased pattern of urbanization, industrialization and modernization and the related environmental effects in Africa, future longitudinal studies on specific environmental risk factors or mediators of DED and MGD are necessary to ascertain the MGD and DED situation in Ghana and Africa at large.
© 2020 Osae et al.

Entities:  

Keywords:  dry eye; dysfunctional tear syndrome; meibomian gland dysfunction; ocular surface

Year:  2020        PMID: 33262570      PMCID: PMC7699986          DOI: 10.2147/OPTH.S275584

Source DB:  PubMed          Journal:  Clin Ophthalmol        ISSN: 1177-5467


  29 in total

Review 1.  The international workshop on meibomian gland dysfunction: report of the subcommittee on the epidemiology of, and associated risk factors for, MGD.

Authors:  Debra A Schaumberg; Jason J Nichols; Eric B Papas; Louis Tong; Miki Uchino; Kelly K Nichols
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-03-30       Impact factor: 4.799

Review 2.  Epidemiology of dry eye disease in Africa: The sparse information, gaps and opportunities.

Authors:  A E Osae; U Gehlsen; J Horstmann; S Siebelmann; M E Stern; D B Kumah; P Steven
Journal:  Ocul Surf       Date:  2017-01-05       Impact factor: 5.033

3.  Bacteriological profile of ocular surface flora in meibomian gland dysfunction.

Authors:  Shao Dan Zhang; Jing Na He; Tong Tong Niu; Chiu Yeung Chan; Chun Yang Ren; Shan Shan Liu; Yang Qu; Kam Lung Chong; Hai Lin Wang; Jun Tao; Chi Pui Pang
Journal:  Ocul Surf       Date:  2017-01-14       Impact factor: 5.033

4.  Meibography and meibomian gland measurements in ocular graft-versus-host disease.

Authors:  L A Engel; S Wittig; F Bock; L Sauerbier; C Scheid; U Holtick; J-M Chemnitz; M Hallek; C Cursiefen; P Steven
Journal:  Bone Marrow Transplant       Date:  2015-04-20       Impact factor: 5.483

5.  Trachoma and vitamin A deficiency.

Authors:  J Schémann; D Malvy; D Sacko; L Traore
Journal:  Lancet       Date:  2001-05-26       Impact factor: 79.321

6.  Tear cytokine profiles in dysfunctional tear syndrome.

Authors:  Helene Lam; Lauren Bleiden; Cintia S de Paiva; William Farley; Michael E Stern; Stephen C Pflugfelder
Journal:  Am J Ophthalmol       Date:  2008-11-07       Impact factor: 5.258

7.  Evaluation of community intervention with pit latrines for trachoma control in Ghana, Mali, Niger and Nigeria.

Authors:  Lisa A Rotondo; Jeremiah Ngondi; Ann F Rodgers; Jonathan D King; Yaya Kamissoko; Ali Amadou; Nimzing Jip; Elizabeth A Cromwell; Paul M Emerson
Journal:  Int Health       Date:  2009-12       Impact factor: 2.473

Review 8.  Vitamin A supplements for preventing mortality, illness, and blindness in children aged under 5: systematic review and meta-analysis.

Authors:  Evan Mayo-Wilson; Aamer Imdad; Kurt Herzer; Mohammad Yawar Yakoob; Zulfiqar A Bhutta
Journal:  BMJ       Date:  2011-08-25

9.  Outdoor Air Pollution and Pterygium in Korea.

Authors:  Ki Woong Lee; Yoon Hyeong Choi; Sung Ha Hwang; Hae Jung Paik; Mee Kum Kim; Won Ryang Wee; Dong Hyun Kim
Journal:  J Korean Med Sci       Date:  2017-01       Impact factor: 2.153

10.  Assessment of meibomian glands using a custom-made meibographer in dry eye patients in Ghana.

Authors:  Eugene Appenteng Osae; Reynolds Kwame Ablorddepey; Jens Horstmann; David Ben Kumah; Philipp Steven
Journal:  BMC Ophthalmol       Date:  2018-08-16       Impact factor: 2.209

View more
  2 in total

1.  A Practical Approach to Severity Classification and Treatment of Dry Eye Disease: A Proposal from the Mexican Dry Eye Disease Expert Panel.

Authors:  Alejandro Rodriguez-Garcia; Alejandro Babayan-Sosa; Arturo Ramirez-Miranda; Concepcion Santa Cruz-Valdes; Everardo Hernandez-Quintela; Julio C Hernandez-Camarena; Nallely Ramos-Betancourt; Regina Velasco-Ramos; Raul E Ruiz-Lozano
Journal:  Clin Ophthalmol       Date:  2022-04-28

Review 2.  Meibomian Gland Dysfunction in Ocular Graft vs. Host Disease: A Need for Pre-Clinal Models and Deeper Insights.

Authors:  Eugene Appenteng Osae; Philipp Steven
Journal:  Int J Mol Sci       Date:  2021-03-29       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.